CD274 and neoplasm: To analyze the anticancer effect of Man@pSiNP‐erastin treatment combined with anti‐PD‐L1 therapy in vivo, Hepa1‐6 tumor‐bearing C57BL/6 male mice were randomly divided into four groups (6 mice/group) and treated with Man@pSiNP, Man@pSiNP‐erastin, anti‐PD‐L1, or a combination of Man@pSiNPs‐erastin and anti‐PD‐L1, separately.